Search alternatives:
026 decrease » _ decrease (Expand Search), nn decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
026 decrease » _ decrease (Expand Search), nn decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
16801
Table_13_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
16802
Table_12_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
16803
Table_14_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
16804
Table_3_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
16805
Table_11_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
16806
Table_15_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
16807
Loss of MLL1 in adult mice.
Published 2021“…<p>(A) Giemsa-stained sections from the femur of <i>Mll1</i><sup><i>FC/+; RC/+</i></sup> and <i>Mll1</i><sup><i>FC/FC; RC/+</i></sup> mice. …”
-
16808
Table_5_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
16809
Data_Sheet_1_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.PDF
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
16810
Table_9_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
16811
Table_4_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
16812
Image 3_CS Ratio is an immune-related prognostic biomarker for cervical cancer.tiff
Published 2025“…The CS polarization state reflects a highly coordinated network of pro-tumor anti-tumor variables offering a simplified yet effective immune response indicator for the complex TME. …”
-
16813
Image 2_CS Ratio is an immune-related prognostic biomarker for cervical cancer.tiff
Published 2025“…The CS polarization state reflects a highly coordinated network of pro-tumor anti-tumor variables offering a simplified yet effective immune response indicator for the complex TME. …”
-
16814
Image 1_CS Ratio is an immune-related prognostic biomarker for cervical cancer.tiff
Published 2025“…The CS polarization state reflects a highly coordinated network of pro-tumor anti-tumor variables offering a simplified yet effective immune response indicator for the complex TME. …”
-
16815
S1 Data -
Published 2025“…Notably, moderate (D2) and severe (D3) drought treatments led to negative GD values. GD decreased by 23.79%, 114.85%, and 175.50% for D1, D2, and D3 treatments, respectively, while reductions of 40.00%, 73.33%, and 90.00% in GD were observed compared to the control (CK). …”
-
16816
S3 Data -
Published 2025“…Notably, moderate (D2) and severe (D3) drought treatments led to negative GD values. GD decreased by 23.79%, 114.85%, and 175.50% for D1, D2, and D3 treatments, respectively, while reductions of 40.00%, 73.33%, and 90.00% in GD were observed compared to the control (CK). …”
-
16817
S2 Data -
Published 2025“…Notably, moderate (D2) and severe (D3) drought treatments led to negative GD values. GD decreased by 23.79%, 114.85%, and 175.50% for D1, D2, and D3 treatments, respectively, while reductions of 40.00%, 73.33%, and 90.00% in GD were observed compared to the control (CK). …”
-
16818
S5 Data -
Published 2025“…Notably, moderate (D2) and severe (D3) drought treatments led to negative GD values. GD decreased by 23.79%, 114.85%, and 175.50% for D1, D2, and D3 treatments, respectively, while reductions of 40.00%, 73.33%, and 90.00% in GD were observed compared to the control (CK). …”
-
16819
S6 Data -
Published 2025“…Notably, moderate (D2) and severe (D3) drought treatments led to negative GD values. GD decreased by 23.79%, 114.85%, and 175.50% for D1, D2, and D3 treatments, respectively, while reductions of 40.00%, 73.33%, and 90.00% in GD were observed compared to the control (CK). …”
-
16820
S4 Data -
Published 2025“…Notably, moderate (D2) and severe (D3) drought treatments led to negative GD values. GD decreased by 23.79%, 114.85%, and 175.50% for D1, D2, and D3 treatments, respectively, while reductions of 40.00%, 73.33%, and 90.00% in GD were observed compared to the control (CK). …”